Predictive Oncology (FRA:S1K) 5-Year EBITDA Growth Rate : 56.40% (As of Jun. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Predictive Oncology 5-Year EBITDA Growth Rate?

Predictive Oncology's EBITDA per Share for the three months ended in Jun. 2024 was €-0.70.

During the past 3 years, the average EBITDA Per Share Growth Rate was 44.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 56.40% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 58.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Predictive Oncology was 69.70% per year. The lowest was 41.80% per year. And the median was 63.80% per year.

Competitive Comparison of Predictive Oncology's 5-Year EBITDA Growth Rate

For the Medical Instruments & Supplies subindustry, Predictive Oncology's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Predictive Oncology's 5-Year EBITDA Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Predictive Oncology's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Predictive Oncology's 5-Year EBITDA Growth Rate falls into.

Predictive Oncology 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Predictive Oncology (FRA:S1K) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Predictive Oncology 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Predictive Oncology's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Predictive Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Predictive Oncology Inc (FRA:S1K) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

POAI:USA

Address

No.91 43rd Street, Suite 110, Pittsburgh, PA, USA, 55121

Website

https://www.predictive-oncology.com

Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.

Predictive Oncology Headlines

No Headlines